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G-induced 26:S-24
glomerular size-selective barrier, nephritis 151
glomerular, progressive renal disease 25:S-1 19
glucocorticoids in BP regulation 25:S-49
ionic control of blood vessels 25:S-2
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pre-eclampsia in pregnancy, post-partum 704
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